Note: Scendia Biologics's revenues are gauged from an analysis of company filings.
Scendia Biologics's Income Statement (based on Industry Averages)
Scendia Biologics P&L
$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit
Trademark Applications
Trademark applications show the products and services that Scendia Biologics is developing and marketing.
Scendia Biologics doesn't have any recent trademark applications, indicating Scendia Biologics is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
ALLOCYTE Allograft based biologics products, namely, an advanced cellular bone matrix for promoting bone formation, excluding wound healing and/or stem cell products
07/19/2021
BIFORM Bone void fillers consisting of natural materials
04/04/2019
See all trademarks and details in the Full Report.
Market Share of Scendia Biologics's Largest Competitors
A competitive analysis shows these companies are in the same general field as Scendia Biologics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Scendia Biologics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Scendia Biologics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.